Septerna Establishes $150M At-The-Market Equity Offering Program
SEPN has more than doubled off its 52-week low of $4.66.
Summary
Septerna, Inc. has filed an S-3ASR registration statement to establish an At-The-Market (ATM) equity offering program, allowing it to sell up to $150 million of common stock from time to time, following recent positive clinical trial data and strong financial results.
Key Events · Financing and Capital Events · SEPN
-
New ATM Program Established
Septerna entered into an ATM Equity Offering Sales Agreement with BofA Securities, Inc., enabling the sale of up to $150 million in common stock from time to time.
-
Potential Share Dilution
The program authorizes the company to issue additional shares, which could result in substantial dilution for existing shareholders if fully utilized.
-
Strategic Capital Raise
This filing follows closely on the heels of positive Phase 1 clinical trial results and strong Q4 2025 financial results, suggesting an opportunistic capital raise to fund R&D and extend its cash runway.
Analysis · SEPN · Life Sciences
Septerna, Inc. has established an At-The-Market (ATM) equity offering program, allowing it to sell up to $150 million of common stock from time to time. This move provides the company with significant financial flexibility, following recent positive Phase 1 clinical trial data and strong Q4 2025 financial results. While the potential issuance of shares under this program could lead to substantial dilution for current shareholders, the timing suggests an opportunistic capital raise to further strengthen its balance sheet and fund ongoing research and development and clinical programs. Investors should monitor the pace and pricing of any future share sales under this program, as actual dilution will depend on the amount and price at which shares are sold.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 30% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SEPN was trading at $28.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $4.66 to $32.63. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.